Introduction {#s1}
============

The tumor microenvironment (TME) is the internal environment where a tumor develops and where a functional complex of interactions among tumor cells, stromal cells, and tumor-infiltrating lymphocytes (TIL) takes place. The TME status reflects the interaction between the host immune response and tumor progression. Typically, TIL is a key component in TME that reflects the anti-tumor immune response in the host. It is also crucial for suppressing cancer progression and has implications for the success of the host anti-tumor immune response against certain solid tumors ([@B1]--[@B3]). A tertiary lymphoid structure (TLS), an organ-like structure, recruits naive T and B cells into the tumor site via chemokines or cytokines. TLS is similar to a secondary lymphoid structure (SLO) in terms of structure and function ([@B4]--[@B7]). Despite the known role of TLS in tumor progression, its formation and function in solid tumors have not been thoroughly explained so far. In recent studies, TLS has been detected in primary ([@B8]) and metastatic tumors ([@B7]), and the high density of TLS has been found to be positively correlated with the prognosis for colorectal ([@B9]), lung ([@B10]), breast cancer ([@B11]), and malignant melanoma ([@B12]). However, the mechanisms that promote an anti-tumor immune response, as well as the association between TLS and patient prognosis, in gastric cancer (GC) remain unclear ([@B13]). High endothelial venules (HEVs) are the characteristic vessels of SLO and TLS. Of note, MECA-79 ([@B14], [@B15]) expressed on the HEVs binds to CD62L, and its expression on lymphocytes causes the latter to roll along HEVs and infiltrate the TME ([@B12]). Based on the results from the aforementioned studies, HEVs are the crucial sites for lymphocyte recruitment and TLS accounts for an important source of TIL. The aim of the present study was to assess the distribution and the prognostic value of TLS in GC by reviewing a large number of cases. In addition, immunohistochemically stained MECA-79 and CD21 were used to verify the accuracy of the morphological TLS scoring system. The association among TLS, clinicopathological parameters, and patient prognosis was analyzed.

Materials and Methods {#s2}
=====================

Patient and Tissue Samples
--------------------------

In this retrospective cohort study, data were collected from the Department of Pathology of the Third Affiliated Hospital of Soochow University between 2002 and 2008. The patient inclusion criteria were as follows: (i) patients pathologically diagnosed with primary gastric adenocarcinoma, (ii) patients who were naïve to preoperative chemotherapy or radiotherapy, (iii) patients with adequate formalin-fixed and paraffin-embedded (FFPE) tissue blocks, (iv) patients with at least one slide containing the tumor invasive margin (IM), and (v) patients with complete medical records and follow-up information. Finally, a total of 1,033 cases were included in this study. To construct and validate the analyses for TLS, 914 patients were enrolled into the primary cohort between 2004 and 2008, while the remaining patients (119 cases) were included as the external validation cohort between 2002 and 2003. The Tumor Pathological Staging System (8th Edition) of the Union for International Cancer Control/American Joint Committee on Cancer was adopted for GC classification. The patient survival intervals were available and dated to the end of January 2018. The study protocol was approved by the Ethics Committee of Soochow University and conducted in accordance with the Declaration of Helsinki.

Histopathological Evaluation of Sections Using Hematoxylin and Eosin Staining
-----------------------------------------------------------------------------

The aim of the present study was to evaluate the methodology for a TLS scoring system in GC. TLS evaluation was retrospectively performed using H&E staining. In brief, the tumor tissue sections were reviewed independently by four pathologists who were trained on the TLS scoring system and blinded to the clinical data. During the subsequent scoring process, any problematic case was discussed jointly by two or more of the aforementioned pathologists. No uniform standard was available for the histopathological TLS scoring system, and TLS was defined as a cumulative area of ectopic lymphocytes (\>200-fold microscopic field; 1 mm in diameter). According to the criterion of previous studies ([@B16]--[@B18]), the tumor area was subdivided in the center of the tumor (CT) and the IM. Next, all available complete sections were morphologically analyzed for the (i) number of TLS and (ii) percentage of the CT or the IM region occupied by TLS in 10% increments (5 and 95% were allowed at extremes) ([@B19]). Subsequently, TLS evaluation was conducted in both the CT and the IM regions separately, and the number and the percentage were then incorporated. Following the TLS assessment, a set of TLS scores was obtained, including (i) TLS-CT number (TLS-CT-N), which indicated the number of TLS in the CT region, (ii) TLS-CT density (TLS-CT-D), which was calculated by multiplying a score of 1 with the percentage of TLS in the CT region and reflected the distribution and the density of TLS in the CT region, (iii) TLS-IM number (TLS-IM-N), which represented the number of TLS in the IM region, (iv) TLS-IM density (TLS-IM-D), which was calculated by multiplying a score of 3 with the percentage of TLS in the IM region and reflected the distribution and the density of TLS in the IM region, and (v) TLS-SUM, which indicated the TLS total score in both the CT and the IM regions (namely, the sum of TLS-CT-D and TLS-IM-D).

The Repeatability and the Accuracy of TLS Evaluation
----------------------------------------------------

The repeatability and the accuracy of the TLS evaluation were double-checked. First, the methodology of the TLS evaluation was obtained in the primary cohort, and the TLS evaluation was validated in the validation cohort. Secondly, immunohistochemically stained MECA-79 and CD21 were used to verify the accuracy of the morphological evaluation.

A total of 63 randomly selected cases in the primary cohort were immunologically stained for MECA-79 (1:125 dilution, [RRID: AB_493556](https://scicrunch.org/resolver/RRID:AB_493556), BioLegend). HEVs, the special venules in TLS, were selected to verify the accuracy of the TLS scoring system. MECA-79 recognized the sulfate-dependent carbohydrate epitopes expressed on the endothelial cells of HEVs. Meanwhile, 119 cases in the validation cohort were immunologically stained for CD21 (ready-to-use, Cat\# RMA-0811, MXB Biotechnologies). The follicular dendritic cells (FDC) marked by CD21 were regarded as a representative lymphoid follicle in TLS. The FFPE tumor tissues were cut into 4-μm-thick sections, dewaxed in xylene, rehydrated, and exposed to gradient ethanol solutions. Cases with a positive immunohistochemical staining for MECA-79 and CD21 in the cytoplasm were considered as positive cases. The number of MECA-79^+^ vessels and CD21^+^ lymphoid follicles was recorded.

Statistical Analysis
--------------------

IBM SPSS statistical software v24.0 (IBM Corp) and GraphPad Prism 6 (GraphPad Software) were used for the statistical analysis. Correlation analysis, χ^2^ test, consistency test, Kaplan--Meier survival analysis, and Cox regression analysis were used as appropriate. All statistical analyses were two-sided, and *P* \< 0.05 was considered to indicate a statistically significant difference.

Results {#s3}
=======

Prognostic Value of TLS in GC
-----------------------------

The analysis was conducted based on data from the primary cohort. To make the scoring system simpler for statistical analysis, the variables were transformed into binary variables according to the median ([Supplemental Table I](#SM2){ref-type="supplementary-material"}). As shown by the Kaplan--Meier survival analysis, high levels of TLS-CT-D or TLS-SUM were correlated with superior survival in patients (χ^2^ = 4.013, *P* = 0.045; χ^2^ = 4.298, *P* = 0.038, [Table 1](#T1){ref-type="table"}, [Figure 1A](#F1){ref-type="fig"}). In addition, the contribution of TLS to the prognostic power of each pTN stage was evaluated ([Table 1](#T1){ref-type="table"}). The results suggested that TLS-SUM had a protective effect on patients with pTN stages II and III (*P* = 0.027, *P* = 0.042, [Table 1](#T1){ref-type="table"}, [Figures 1B,C](#F1){ref-type="fig"}). To verify the statistical analysis results, an external validation cohort was used to test the variables. The prognostic value of TLS-SUM in the validation cohort was the same as that in the primary cohort (*P* = 0.024, *P* = 0.035, [Table 1](#T1){ref-type="table"}, [Figures 1D--F](#F1){ref-type="fig"}). High levels of TLS-IM-N were correlated with better survival in pTN stage II patients from the primary and the validation cohorts (*P* = 0.006, *P* = 0.034, [Table 1](#T1){ref-type="table"}, [Supplemental Figures 1A,B](#SM1){ref-type="supplementary-material"}). A total of 325 cases with different levels of TLS-CT-D and TLS-IM-N were grouped: 169 TLS-CT-D^high^ TLS-IM-N^low^ cases and 156 TLS-CT-D^low^ TLS-IM-N^high^ ones. The TLS-CT-D^high^ TLS-IM-N^low^ was correlated with better survival in all patients and pTN stage I patients from the primary cohort (*P* = 0.031, *P* = 0.032, [Supplemental Figures 1C,D](#SM1){ref-type="supplementary-material"}).

###### 

Hierarchical K--M survival analysis of tertiary lymphoid structure (TLS) and pathological tumor and lymph node (pTN).

  **Hierarchical definition**   **TLS in primary (high/low)**   **χ^**2**^**   ***P* value**   **TLS in validation (high/low)**   **χ^**2**^**   ***P* value**                         
  ----------------------------- ------------------------------- -------------- --------------- ---------------------------------- -------------- --------------- ------------- ------- -----------
  TLS-CT-N                      I                               133/103        148.6/144.0     0.547                              0.460          14/13           138.6/130.3   0.215   0.643
                                II                              114/160        103.6/89.0      3.071                              0.080          11/20           97.0/81.5     0.213   0.645
                                III                             223/181        48.3/39.5       2.912                              0.088          24/37           57.9/40.1     1.701   0.192
                                I--III                          470/444        90.1/81.7       3.326                              0.068          49/70           90.3/68.8     2.632   0.105
  TLS-CT-D                      I                               139/97         148.4/144       0.650                              0.420          12/15           141.7/129.1   0.454   0.500
                                II                              119/155        103.4/88.4      3.278                              0.070          11/20           97.0/81.5     0.213   0.645
                                III                             225/179        47.7/40.2       2.220                              0.136          25/36           67.7/32.4     5.261   **0.022**
                                I--III                          483/431        90.3/81.0       4.013                              **0.045**      48/71           93.4/66.9     3.401   0.065
  TLS-IM-N                      I                               104/132        139.1/152.4     3.323                              0.068          7/20            114.7/141.3   0.447   0.504
                                II                              137/137        105.8/84.1      7.552                              **0.006**      13/18           121.2/61.6    4.519   **0.034**
                                III                             229/175        45.7/42.5       0.977                              0.323          18/43           74.9/35.3     5.417   **0.020**
                                I--III                          470/444        84.0/87.9       0.555                              0.456          38/81           98.7/67.3     4.825   **0.028**
  TLS-IM-D                      I                               106/130        139.6/152.1     2.826                              0.093          7/20            114.7/141.3   0.447   0.504
                                II                              138/136        105.4/84.3      7.160                              **0.007**      14/17           114.9/63.3    3.760   0.053
                                III                             230/174        45.5/42.6       0.848                              0.357          18/43           74.9/35.3     5.417   **0.020**
                                I--III                          474/440        84.1/87.8       0.460                              0.498          39/80           97/67.8       4.487   **0.034**
  TLS-SUM                       I                               127/109        145.3/148.0     0.001                              0.969          8/19            122.5/140.0   0.191   0.662
                                II                              120/154        105.1/87.0      4.866                              **0.027**      12/19           127.7/60.8    5.126   **0.024**
                                III                             210/194        49.3/38.7       4.153                              **0.042**      17/44           76.2/35.5     4.424   **0.035**
                                I--III                          457/457        90.7/81.1       4.298                              **0.038**      37/82           103.7/65.9    5.928   **0.015**

*Values in bold signify p \< 0.05*.

![The hierarchical Kaplan--Meier survival curves for TLS-SUM in GC. TLS-SUM^hi^ is associated with better prognosis in GC patients from the primary cohort **(A)** and the validation cohort **(D)**. The contribution of TLS to the prognostic power of pTN stages II and III patients was evaluated from the primary cohort **(B,C)** and the validation cohort **(E,F)**. TLS, tertiary lymphoid structure; GC, gastric cancer.](fonc-10-00980-g0001){#F1}

Cox regression analysis was performed to evaluate the prognostic significance of TLS and the clinicopathological parameters \[including age, tumor size, lymph node (LN) metastasis, vessel invasion, histopathological grade, pTN stage, WHO subtypes, and sets of TLS\]. In the univariate Cox regression analysis, TLS-CT-D, TLS-SUM, and all the clinicopathological parameters were found to be independent prognostic factors for overall survival. Moreover, the LN metastasis information was contained in the pTN stage parameter and excluded from the multivariate Cox regression model. The multivariate Cox regression analysis was performed based on the TLS-CT-D and the TLS-SUM data \[hazard ratio (HR) = 0.833, 95% CI: 0.702--0.989, *P* = 0.037; HR = 0.794, 95% CI: 0.668--0.942, *P* = 0.008, [Supplemental Table II](#SM3){ref-type="supplementary-material"}\]. Of note is that TLS had a HR score of \<1, suggesting that the high level of TLS showed a protective effect on patient survival. To verify the statistical analysis, Cox regression analysis was performed in the validation cohort. In univariate and multivariate Cox regression analyses, TLS-SUM was identified as the independent prognostic factor (HR = 0.496, 95% CI: 0.252--0.973, *P* = 0.041; HR = 0.411, 95% CI: 0.229--0.740, *P* = 0.003, [Table 2](#T2){ref-type="table"}).

###### 

Univariate and multivariate Cox regression analyses of tertiary lymphoid structure (TLS)-SUM and clinicopathological parameters.

  **Clinicopathological parameters**   **Multivariate analysis in primary**   **Multivariate analysis in validation**                                         
  ------------------------------------ -------------------------------------- ----------------------------------------- ------------- ------- --------------- -----------
  Age (≤ 50/\>50)                      1.954                                  1.472--2.594                              **\<0.001**   1.924   1.010--3.667    **0.047**
  Tumor size (≤ 5 cm/\>5 cm)           1.101                                  0.917--1.321                              0.303         1.272   0.740--2.189    0.384
  Vessel invasion (-/+)                1.209                                  1.013--1.443                              **0.035**     1.316   0.648--2.670    0.448
  Histological grade                                                                                                                                          
      Well                                                                    Reference                                                       Reference       
      Moderately                       0.862                                  0.414--1.794                              0.691         4.122   0.506--33.566   0.186
      Poor                             1.094                                  0.520--2.301                              0.812         4.525   0.539--37.978   0.164
  pTN (I--III)                                                                                                                                                
      I                                                                       Reference                                                       Reference       
      II                               3.295                                  2.290--4.742                              **\<0.001**   2.343   0.988--5.558    0.053
      III                              8.334                                  5.788--12.000                             **\<0.001**   3.246   1.367--7.705    **0.008**
  WHO subtypes                                                                                                                                                
      Tubular                                                                 Reference                                                       Reference       
      Mucinous                         0.780                                  0.579--1.052                              0.103         0.636   0.300--1.350    0.239
      Papillary                        1.311                                  0.899--1.913                              0.160         0.739   0.292--1.872    0.523
      Poorly cohesive                  1.006                                  0.795--1.273                              0.962         0.903   0.382--2.137    0.816
      Undifferentiated                 1.182                                  0.861--1.624                              0.301         2.207   1.000--4.873    0.050
  TLS-SUM (low/high)                   0.794                                  0.668--0.942                              **0.008**     0.411   0.229--0.740    **0.003**

*Values in bold signify p \< 0.05*.

Association Between TLS and Clinicopathological Parameters
----------------------------------------------------------

Details of the clinicopathological parameters, TLS-SUM, and TLS-CT-D are presented in [Table 3](#T3){ref-type="table"}. TLS was significantly correlated with tumor size, histological grade, pTN stage, and WHO subtype (*P* \< 0.05, [Table 2](#T2){ref-type="table"}). These data revealed that the high levels of TLS were associated with clinicopathological parameters, such as smaller tumor size and earlier pTN stage, and indicated better prognosis. TLS might serve as a potent prognostic indicator, which can be as crucial as a clinicopathological parameter.

###### 

Relationship between tertiary lymphoid structure (TLS) and clinicopathological parameters.

  **Clinicopathological parameters**   **TLS-SUM**   ***χ*^2^**   ***P* value**   **TLS-CT-D**   ***χ*^2^**   ***P* value**   **TLS-IM-N**   ***χ*^2^**   ***P* value**                 
  ------------------------------------ ------------- ------------ --------------- -------------- ------------ --------------- -------------- ------------ --------------- ----- ------- -----------
  Age (year)                                                                                                                                                                            
      \>50                             387           403          2.389           0.122          410          380             2.091          0.148        405             385   0.057   0.811
       ≤ 50                            70            54                                          73           51                                          65              59            
  Tumor size (cm)                                                                                                                                                                       
      \>5                              220           250          3.942           **0.047**      225          245             9.599          **0.002**    250             220   1.212   0.271
       ≤ 5                             237           207                                         258          186                                         220             224           
  Lymph node metastasis                                                                                                                                                                 
      Yes                              271           292          2.040           0.153          290          273             1.048          0.306        299             264   1.668   0.196
      No                               186           165                                         193          158                                         171             180           
  Vessel invasion                                                                                                                                                                       
      Yes                              157           158          0.005           0.945          155          160             2.553          0.110        169             146   0.956   0.328
      No                               300           299                                         328          271                                         301             298           
  Histological grade                                                                                                                                                                    
       Well                            22            20           6.512           **0.039**      26           16              7.396          **0.025**    17              25    2.795   0.247
      Moderately                       146           183                                         155          174                                         165             164           
      Poor                             289           254                                         302          241                                         288             255           
  pTN stage                                                                                                                                                                             
      I                                127           109          6.226           **0.044**      139          97              14.531         **0.001**    104             132   9.808   **0.007**
      II                               120           154                                         119          155                                         137             137           
      III                              210           194                                         225          179                                         229             175           
  WHO subtypes                                                                                                                                                                          
      Tubular                          296           277          24.119          **\<0.001**    309          264             15.867         **0.003**    304             269   7.781   0.100
      Mucinous                         37            48                                          47           38                                          40              45            
      Papillary                        9             39                                          13           35                                          16              32            
      Poorly cohesive                  84            62                                          85           61                                          78              68            
      Undifferentiated                 31            31                                          29           33                                          32              30            

*Values in bold signify p \< 0.05*.

Accuracy of Morphological Evaluation of TLS
-------------------------------------------

According to the abovementioned analyses, TLS-SUM was screened as the representative of morphological TLS evaluation. Immunohistochemical staining of MECA-79 and CD21 was used to verify the accuracy of the morphological TLS evaluation.

Based on a statistical correlation analysis, the score of TLS-SUM was positively correlated with the number of MECA-79^+^ vessels (*r* = 0.696, *P* \< 0.001, [Supplemental Table III](#SM4){ref-type="supplementary-material"}, [Figures 2A--C](#F2){ref-type="fig"}). In a subsequent statistical analysis, all variables were transformed into binary variables. Thereafter, all 63 patients were divided into two groups according to the presence or the absence of MECA-79^+^ vessels, including 40 (63.5%) MECA-79^+^ cases and 23 (36.5%) MECA-79^−^ ones. According to the TLS-SUM, the 63 patients were subdivided into 44 high-level cases and 17 low-level cases. The results of the χ^2^ test and consistency analysis revealed a significant consistency agreement between MECA-79 and TLS-SUM (χ^2^ = 18.849, *P* \< 0.001, κ = 0.565, *P* \< 0.001, [Supplemental Table III](#SM4){ref-type="supplementary-material"}).

![Histopathological observation and immunohistochemical verification of TLS. The TLS present in GC tissue **(A--D)** (blue arrow). MECA-79 and CD21 were used to verify the accuracy of the morphological evaluation of TLS. HEVs **(A--C)** (red arrow, MECA-79^+^) and venules **(A--C)** (black arrow, MECA-79^−^) are shown closing around the TLS. CD21-marked FDCs **(E,F)** (blue arrow, CD21^+^) are observed in the TLS. TLS, tertiary lymphoid structure; GC, gastric cancer; HEVs, high endothelial venules; FDCs, follicular dendritic cells.](fonc-10-00980-g0002){#F2}

The CD21-marked FDC in the B cell follicles was also used to verify the accuracy of the morphological TLS evaluation. Upon analysis, the score of TLS-SUM was positively correlated with the number of CD21^+^ lymphoid follicles (*r* = 0.924, *P* \< 0.001, [Supplemental Table III](#SM4){ref-type="supplementary-material"}, [Figures 2D--F](#F2){ref-type="fig"}). The patients in the validation cohort were divided into two groups, according to the median: 51 CD21^hi^ cases and 68 CD21^low^ cases, with 37 cases having high levels of TLS-SUM and 82 low-level cases. Furthermore, the χ^2^ and consistency tests revealed a significant consistency between CD21 and TLS-SUM (χ^2^ = 71.593, *P* \< 0.001, κ = 0.751, *P* \< 0.001, [Supplemental Table III](#SM4){ref-type="supplementary-material"}).

Discussion {#s4}
==========

TLS, an organ-like structure of the ectopic aggregated lymphocytes, was first identified in chronic inflammation and autoimmune diseases ([@B5]--[@B7]). In such pathological structures, tissues that harbor tumor antigens are infiltrated by cellular or molecular effectors of the immune system, which are then organized anatomically and functionally as those in SLO with B follicles and T-zone formation ([@B9]). TLS is a potential functional immune site for T lymphocyte activation, B cell maturation, and antibody production. According to recent studies, TLS has been detected in various tumors and found to be associated with favorable prognosis ([@B7]--[@B12], [@B20]--[@B22]). Nonetheless, there are no uniform histopathological diagnostic standards for TLS, and the prognostic value of TLS distribution remains unclear in the field of GC ([@B4], [@B13]). In the present study, a set of TLS scores was obtained by reviewing the H&E-stained sections. Based on the immunohistochemical detection of MECA-79 and CD21, the morphological TLS evaluation was accurate, which was verified by the external validation testing. By comparing the TLS between the CT and the IM regions, it was found that the presence of TLS in the CT region was correlated with better prognosis than that in the IM region, which was a novel finding. The gastric wall is anatomically classified into four layers: mucosa, submucosa, muscular layer, and serosa. The submucosa and the subserosa contain loose connective tissue as well as normal lymph nodes and ectopic lymphoid aggregates under homeostatic conditions as part of the digestion-associated lymphoid tissues, which play an essential role in the gastrointestinal immune response. The IM region located in the submucosa and the subserosa correspond to pTN stage I or III. In these two layers, the TLS may be associated with tumors or pre-exist, making them hard to distinguish using H&E-staining-based diagnosis. On the contrary, the muscular layer is composed of smooth muscle and barely contains lymphatic tissue in the normal gastric tissue. The IM region located in the muscular layer corresponding to pTN stage II and the TLS-IM were mainly associated with tumors in GC tissue. The results of the hierarchical Kaplan--Meier analysis confirmed this. High levels of TLS-IM were correlated with better survival in pTN stage II patients, but no correlation with survival was identified in pTN stages I--III patients. TLS-CT-D^high^ TLS-IM-N^low^ was correlated with better survival in all patients and in pTN stage I patients. Therefore, it is necessary that the ability to make this distinction be improved in future studies.

The formation and the function of TLS in solid tumors have not yet been thoroughly explained. At the cancer site, TLS may trigger a cancer-associated inflammation, and it is a crucial site for the production of antibodies that exert important effects on the polarization of macrophages and myeloid cells ([@B23]); this way, the derived suppressor cells promote cancer progression ([@B24]). Conversely, the antitumor immune response originating from TLS can potentially control tumor invasion and metastasis, which can thus enhance the efficiency and the specificity of T-cell priming and boost a faster T-cell reaction to tumor antigens *in situ* ([@B9], [@B25]). In addition, the present study also showed that TLS-SUM and TLS-CT-D were significantly correlated with tumor size, pTN stage, and histological grade. According to the above results, TLS^hi^ was associated with better prognosis for GC patients since TLS was a potential regulatory factor of tumor progression and metastasis. Malignant tumors were treated under the standard therapeutic guidelines based on TNM staging. In the present study, the prognostic power of TLS at different pTN stages was evaluated. As suggested by the Kaplan--Meier survival analysis results, TLS-SUM had a protective effect on patients at pTN stages II and III. Conversely, TLS-SUM expression made no statistically significant difference to patients at pTN stage I. We therefore speculated that the antitumor effect of TLS gradually increased during the early stage of tumor progression, which peaked at the middle and the late stages. This result was consistent with the three stages of tumor progression, namely, immune suppression, immune balance, and immune escape ([@B26]), leading us to believe that lymphocytes in TLS transformed during the tumor progression process and that the functional status of TLS also changed.

Based on univariate and multivariate Cox regression analyses, TLS-SUM was identified as an independent prognostic factor. These data showed that TLS-SUM served as a positive prognostic indicator that was as crucial as the clinicopathological parameters. Furthermore, patients with a high level of TLS-SUM had better prognosis than those with a low level of TLS, which was verified by the correlation between TLS and cancer mortality in the Kaplan--Meier survival analysis. In previous studies, the high density of TLS was found to be associated with good prognosis in tumor patients ([@B9]--[@B12]). This observation was also consistent with the present data in GC, which might interact with novel therapeutic approaches such as immunotherapy in GC ([@B27]--[@B29]). The morphological evaluation results showed clear TLS heterogeneity and prognostic value in GC. Consequently, TLS was predicted to represent a protective host immune system and an antitumor TME in GC. As a crucial factor and target of immunotherapy susceptibility, the lymphocyte components and their functional changes in TLS should be further examined.
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The Kaplan--Meier survival analysis of TL-IM-N at pTN stage II from the primary cohort **(A)** and the validation cohort **(B)**. According to the TLS-CT-D and the TLS-IM-N, the patients were divided into TLS-CT-D^high^ TLS-IM-N^low^ and TLS-CT-D^low^ TLS-IM-N^high^. The Kaplan--Meier survival curves for pTN stages I--III patients **(C)** and pTN stage I patients **(D)** from the primary cohort are shown.
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Subgroup detail of histopathological evaluation of TLS.
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Multivariate Cox Regression Analyses of TLS scores.
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Relationship between TLS-SUM and MECA-79 for HEVs.
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TIL

:   tumor infiltrating lymphocytes

TME

:   tumor microenvironment

TLS

:   tertiary lymphoid structure

GC

:   gastric cancer

CT

:   center of the tumor

IM

:   invasive margin

pTN

:   pathological tumor and lymph node

LN

:   lymph node

OS

:   overall survival

AUC

:   area under the ROC curve.
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